Search

Displaying results 4901 - 4910 of 8698 in total
  1. Drug

    MVA3000

    go.drugbank.com/drugs/DB05040
    Experimental

    MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or

  2. Drug

    humanized SMART Anti-IL-12 Antibody

    go.drugbank.com/drugs/DB05848
    Experimental

    The humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases. … IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases.

  3. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. … ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs.

  4. Drug

    AQ-13

    go.drugbank.com/drugs/DB17749
    Investigational

    AQ-13 is an 4-aminoquinoline analog being investigated for the treatment of malaria.

  5. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    These results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2. … being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)[L12675] with an

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  8. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    VP025 may inhibit immune system activation and protect motoneurons from injury. … VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.

  9. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    With this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  10. Drug

    JTC-801 free base

    go.drugbank.com/drugs/DB17033
    Experimental

    An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]